Siti Setiati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Siti Setiati has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
Rahmi Istanti
Division of Geriatric Medicine, Department of Internal Medicine, Cipto Mangunkusumo Hospital - Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
10 shared publicationsKuntjoro Harimurti
Division of Geriatric Medicine, Department of Internal Medicine, Cipto Mangunkusumo Hospital - Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
6 shared publicationsMuhammad Khifzhon Azwar
Division of Geriatric Medicine, Department of Internal Medicine, Cipto Mangunkusumo Hospital - Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
6 shared publicationsIka Fitriana
Division of Geriatric Medicine, Department of Internal Medicine, Cipto Mangunkusumo Hospital - Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
5 shared publicationsJessica Marsigit
Univ Indonesia, Cipto Mangunkusumo Hosp, Fac Med, Clin Epidemiol & Evidence Based Med, Jakarta, Indonesia
5 shared publicationsLazuardhi Dwipa
Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia.
4 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in SSRN Electronic Journal
Three-Year Overall Survival and Prognostic Factors Among Patients with Colorectal Cancer at Indonesia’s National Cancer Referral Center: A Retrospective Cohort Study with Civil Registration Linkage
Background: Survival data for colorectal cancer in Indonesia come mainly from hospital records with incomplete follow-up. We estimated 3-year overall survival and its prognostic factors at Indonesia’s national cancer referral center, using civil registration linkage to complete vital status.,Methods: This retrospective cohort included adults with histopathologically confirmed colorectal cancer treated at Dharmais National Cancer Center, Jakarta, in 2020–2022. Vital status from medical records was supplemented by linkage with the national civil registration database. Survival was estimated with the Kaplan–Meier method and hazard ratios (HRs) with multivariable Cox regression. Proportional hazards were assessed with Schoenfeld residuals, and non-proportional effects were modelled by splitting follow-up at 12 months.,Results: Of 320 patients (mean age 53.7 years; 33.8% younger than 50 years), 65.9% presented with stage III–IV disease. Linkage reduced the proportion with unascertained vital status before 36 months from 55.0% to 4.4%. There were 187 deaths within 36 months. Three-year overall survival was 39.8% (95% CI 34.3–45.2), with a median of 24.4 months; extreme censoring scenarios gave 37.2–41.6%. Stage IV (adjusted HR 2.84; 95% CI 1.89–4.26) and carcinoembryonic antigen (CEA) >5 µg/L (HR 2.08; 1.47–2.92) were associated with mortality, with proportional effects throughout follow-up. Hypoalbuminemia was associated with mortality during the first 12 months (HR 1.95; 1.30–2.92) but not thereafter (HR 0.96; 0.60–1.54). The apparent benefit of chemotherapy in the first 12 months (HR 0.27; 0.18–0.41) disappeared thereafter (HR 1.48; 0.77–2.86), a pattern consistent with immortal time bias.,Conclusions: Fewer than half of patients survived 3 years, largely reflecting late-stage presentation. Stage and pretreatment CEA carried stable prognostic information, whereas hypoalbuminemia identified early mortality risk only. Civil registration linkage markedly improves the completeness of hospital-based survival estimates, and valid assessment of treatment effects requires time-stamped treatment data.
- 27 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThree-Year Overall Survival and Prognostic Factors Among Patients with Colorectal Cancer at Indonesia’s National Cancer Referral Center: A Retrospective Cohort Study with Civil Registration Linkage
Background: Survival data for colorectal cancer in Indonesia come mainly from hospital records with incomplete follow-up. We estimated 3-year overall survival and its prognostic factors at Indonesia’s national cancer referral center, using civil registration linkage to complete vital status.,Methods: This retrospective cohort included adults with histopathologically confirmed colorectal cancer treated at Dharmais National Cancer Center, Jakarta, in 2020–2022. Vital status from medical records was supplemented by linkage with the national civil registration database. Survival was estimated with the Kaplan–Meier method and hazard ratios (HRs) with multivariable Cox regression. Proportional hazards were assessed with Schoenfeld residuals, and non-proportional effects were modelled by splitting follow-up at 12 months.,Results: Of 320 patients (mean age 53.7 years; 33.8% younger than 50 years), 65.9% presented with stage III–IV disease. Linkage reduced the proportion with unascertained vital status before 36 months from 55.0% to 4.4%. There were 187 deaths within 36 months. Three-year overall survival was 39.8% (95% CI 34.3–45.2), with a median of 24.4 months; extreme censoring scenarios gave 37.2–41.6%. Stage IV (adjusted HR 2.84; 95% CI 1.89–4.26) and carcinoembryonic antigen (CEA) >5 µg/L (HR 2.08; 1.47–2.92) were associated with mortality, with proportional effects throughout follow-up. Hypoalbuminemia was associated with mortality during the first 12 months (HR 1.95; 1.30–2.92) but not thereafter (HR 0.96; 0.60–1.54). The apparent benefit of chemotherapy in the first 12 months (HR 0.27; 0.18–0.41) disappeared thereafter (HR 1.48; 0.77–2.86), a pattern consistent with immortal time bias.,Conclusions: Fewer than half of patients survived 3 years, largely reflecting late-stage presentation. Stage and pretreatment CEA carried stable prognostic information, whereas hypoalbuminemia identified early mortality risk only. Civil registration linkage markedly improves the completeness of hospital-based survival estimates, and valid assessment of treatment effects requires time-stamped treatment data.
- Open Access
PostCOVID-19 Syndrome in Older Adults and the Risk Factors
Objectives: This study aimed to estimate the prevalence of Post-COVID-19 Syndrome among older adults in Indonesia, using time-based definitions of symptoms persisting beyond >4 weeks, >8 weeks, and >12 weeks. Methods: A retrospective cohort study was conducted among 329 older patients (≥60 years) hospitalized with COVID-19 in two tertiary hospitals in Jakarta from January to December 2021. Data on risk factors and persistent symptoms were collected from medical records and interviews. Results: The prevalence of Post-COVID-19 Syndrome was 31% (>4 weeks), 18.24% (>8 weeks), and 10.64% (>12 weeks). Significant predictors included frailty (OR 2.814), immobility during hospitalization (OR up to 4.767), higher number of initial symptoms (OR 2.043), constipation, instability, and sensory impairment during follow-up. Conclusions: Frailty, symptom burden, and geriatric syndromes, particularly immobility are strongly associated with Post-COVID-19 Syndrome in older adults. Clinical Implications: Early identification of frailty, geriatric syndromes (especially immobility), and high initial symptom burden is essential for risk stratification, targeted monitoring, and implementation of preventive and rehabilitative interventions to reduce long-term post-COVID-19 complications in older populations.
Open AccessPostCOVID-19 Syndrome in Older Adults and the Risk Factors
Objectives: This study aimed to estimate the prevalence of Post-COVID-19 Syndrome among older adults in Indonesia, using time-based definitions of symptoms persisting beyond >4 weeks, >8 weeks, and >12 weeks. Methods: A retrospective cohort study was conducted among 329 older patients (≥60 years) hospitalized with COVID-19 in two tertiary hospitals in Jakarta from January to December 2021. Data on risk factors and persistent symptoms were collected from medical records and interviews. Results: The prevalence of Post-COVID-19 Syndrome was 31% (>4 weeks), 18.24% (>8 weeks), and 10.64% (>12 weeks). Significant predictors included frailty (OR 2.814), immobility during hospitalization (OR up to 4.767), higher number of initial symptoms (OR 2.043), constipation, instability, and sensory impairment during follow-up. Conclusions: Frailty, symptom burden, and geriatric syndromes, particularly immobility are strongly associated with Post-COVID-19 Syndrome in older adults. Clinical Implications: Early identification of frailty, geriatric syndromes (especially immobility), and high initial symptom burden is essential for risk stratification, targeted monitoring, and implementation of preventive and rehabilitative interventions to reduce long-term post-COVID-19 complications in older populations.
- 1 April 2026
- Vol. 58 (2) , 133-137
When More Becomes Harm: The Art of Managing Multimorbidity and Multicomplexity in Older Adults.
Multimorbidity and multicomplexity are increasingly becoming the norm in geriatric clinical practice, with a recent Indonesian multicentre study revealing that 80.7% of older outpatients present with multiple coexisting conditions. This editorial discusses the limitations of conventional single-disease guidelines when applied to complex older adults, where simultaneous treatments often lead to polypharmacy, cumulative anticholinergic burdens, and potential adverse outcomes. Highlighting findings from a recent study in Acta Medica Indonesiana, which found polypharmacy in 43.9% of Indonesian geriatric outpatients but a low rate of high anticholinergic burden (1.8%), the editorial underscores the concept of "appropriate polypharmacy" under close clinical monitoring. To effectively navigate multicomplexity defined by the intricate interactions between pathophysiology, treatment effects, functional status, and social context, clinicians must look beyond rigid numerical targets and adopt patient-centered frameworks such as the Geriatrics 5Ms. Central to this approach is the art of judicious deprescribing, utilizing validated criteria like the AGS Beers or STOPP/START to optimize care and minimize harm. Ultimately, modern geriatric care requires a fundamental shift from merely extending lifespan to enhancing health span, focusing on "What Matters Most" to the patient. Integrating these competencies into medical education is vital to prepare future frontline clinicians for the realities of aging populations.
- 1 April 2026
- Vol. 58 (2) , 133-137
When More Becomes Harm: The Art of Managing Multimorbidity and Multicomplexity in Older Adults.
Multimorbidity and multicomplexity are increasingly becoming the norm in geriatric clinical practice, with a recent Indonesian multicentre study revealing that 80.7% of older outpatients present with multiple coexisting conditions. This editorial discusses the limitations of conventional single-disease guidelines when applied to complex older adults, where simultaneous treatments often lead to polypharmacy, cumulative anticholinergic burdens, and potential adverse outcomes. Highlighting findings from a recent study in Acta Medica Indonesiana, which found polypharmacy in 43.9% of Indonesian geriatric outpatients but a low rate of high anticholinergic burden (1.8%), the editorial underscores the concept of "appropriate polypharmacy" under close clinical monitoring. To effectively navigate multicomplexity defined by the intricate interactions between pathophysiology, treatment effects, functional status, and social context, clinicians must look beyond rigid numerical targets and adopt patient-centered frameworks such as the Geriatrics 5Ms. Central to this approach is the art of judicious deprescribing, utilizing validated criteria like the AGS Beers or STOPP/START to optimize care and minimize harm. Ultimately, modern geriatric care requires a fundamental shift from merely extending lifespan to enhancing health span, focusing on "What Matters Most" to the patient. Integrating these competencies into medical education is vital to prepare future frontline clinicians for the realities of aging populations.
- 1 April 2026
- Vol. 58 (2) , 222-252
Quality of Life Research in Cardiovascular Disease in Indonesia: A Scoping Review.
Cardiovascular (CV) disease remains the leading cause of mortality and disability worldwide, particularly in developing countries. Beyond mortality, health-related quality of life (HRQoL) is increasingly recognized as a key outcome and is commonly assessed using patient-reported measures. In Indonesia, cultural and linguistic diversity poses challenges, as most HRQoL instruments have been developed in other contexts. This scoping review aimed to map HRQoL research in Indonesian cardiovascular disease populations by identifying validated instruments, describing study designs and measurement tools, and summarizing HRQoL outcomes. This review was registered on Figshare (DOI: 10.6084/m9.figshare.29218991) and conducted following the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. Literature searches were performed in PubMed, ScienceDirect, Google Scholar, and included grey literature. Studies reporting HRQoL measurement in Indonesian populations were included. A total of 54 studies were included. Both generic and disease-specific HRQoL instruments were identified. Common generic tools included SF-36, SF-12, WHOQOL-BREF, and PedsQL, while disease-specific instruments included MLHFQ, KCCQ, Seattle Angina Questionnaire, AFSS, ASTA, AFEQT, MacNew, and AQUAREL. Only several instruments have been culturally validated, while others were used without prior validation, and some validated tools remained underutilized. HRQoL was influenced by clinical, psychological, behavioral, and social factors. HRQoL research in Indonesia is growing but remains heterogeneous. This mismatch highlights a critical gap between research capacity and real-world implementation in Indonesia. Greater use of standardized tools and longitudinal designs is needed to strengthen patient-centered cardiovascular care.
- 1 April 2026
- Vol. 58 (2) , 222-252
Quality of Life Research in Cardiovascular Disease in Indonesia: A Scoping Review.
Cardiovascular (CV) disease remains the leading cause of mortality and disability worldwide, particularly in developing countries. Beyond mortality, health-related quality of life (HRQoL) is increasingly recognized as a key outcome and is commonly assessed using patient-reported measures. In Indonesia, cultural and linguistic diversity poses challenges, as most HRQoL instruments have been developed in other contexts. This scoping review aimed to map HRQoL research in Indonesian cardiovascular disease populations by identifying validated instruments, describing study designs and measurement tools, and summarizing HRQoL outcomes. This review was registered on Figshare (DOI: 10.6084/m9.figshare.29218991) and conducted following the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. Literature searches were performed in PubMed, ScienceDirect, Google Scholar, and included grey literature. Studies reporting HRQoL measurement in Indonesian populations were included. A total of 54 studies were included. Both generic and disease-specific HRQoL instruments were identified. Common generic tools included SF-36, SF-12, WHOQOL-BREF, and PedsQL, while disease-specific instruments included MLHFQ, KCCQ, Seattle Angina Questionnaire, AFSS, ASTA, AFEQT, MacNew, and AQUAREL. Only several instruments have been culturally validated, while others were used without prior validation, and some validated tools remained underutilized. HRQoL was influenced by clinical, psychological, behavioral, and social factors. HRQoL research in Indonesia is growing but remains heterogeneous. This mismatch highlights a critical gap between research capacity and real-world implementation in Indonesia. Greater use of standardized tools and longitudinal designs is needed to strengthen patient-centered cardiovascular care.
- 1 April 2026
- Vol. 58 (2) , 154-163
Anticholinergic Burden, Falls, and the Concept of Appropriate Polypharmacy in Indonesian Geriatric Clinics: A Multicentre Observational Study.
A high anticholinergic burden (ACB) scale score (≥3) and polypharmacy have been viewed negatively due to possible adverse events. As Indonesian multicentre data in this field are lacking, this study aimed to provide regional data related to ACB, polypharmacy, and falls, and to analyse factors potentially linked to falls. Data from community-dwelling older adults aged ≥60 years were collected in 12 geriatric care centres through history taking and medical records. Bivariate and multivariate analyses were conducted to evaluate the association between covariates and falls. Polypharmacy and high ACB (score ≥3) were observed in 43.9% and 1.8% of 626 older adults, respectively. The five most prescribed drug classes were calcium-channel blockers, angiotensin receptor blockers, statins, beta blockers, and proton pump inhibitors. The three most prescribed drugs with possible anticholinergic activity were furosemide, isosorbide dinitrate, and cetirizine. The prevalence of past-year falls was 16.8%. Falls were associated with age ≥80 years (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.31-4.53), female sex (OR 2.08, 95% CI 1.30-3.31), transient ischaemic attack and cerebrovascular accident (OR 1.97, 95% CI 0.94-4.10), multimorbidity (≥3 co-morbidities) (OR 1.80, 95% CI 1.07-3.03), depression (OR 1.79, 95% CI 1.00-3.23), and polypharmacy (OR 0.65, 95% CI 0.40-1.05). The prevalence of a high ACB score and falls were 1.8% and 16.8%, respectively. Approximately one in two older adults had polypharmacy. We observed a non-significant inverse relationship between polypharmacy and falls. This may possibly suggest appropriate polypharmacy and closer monitoring applied in geriatric settings, which requires further investigation.
- 1 April 2026
- Vol. 58 (2) , 154-163
Anticholinergic Burden, Falls, and the Concept of Appropriate Polypharmacy in Indonesian Geriatric Clinics: A Multicentre Observational Study.
A high anticholinergic burden (ACB) scale score (≥3) and polypharmacy have been viewed negatively due to possible adverse events. As Indonesian multicentre data in this field are lacking, this study aimed to provide regional data related to ACB, polypharmacy, and falls, and to analyse factors potentially linked to falls. Data from community-dwelling older adults aged ≥60 years were collected in 12 geriatric care centres through history taking and medical records. Bivariate and multivariate analyses were conducted to evaluate the association between covariates and falls. Polypharmacy and high ACB (score ≥3) were observed in 43.9% and 1.8% of 626 older adults, respectively. The five most prescribed drug classes were calcium-channel blockers, angiotensin receptor blockers, statins, beta blockers, and proton pump inhibitors. The three most prescribed drugs with possible anticholinergic activity were furosemide, isosorbide dinitrate, and cetirizine. The prevalence of past-year falls was 16.8%. Falls were associated with age ≥80 years (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.31-4.53), female sex (OR 2.08, 95% CI 1.30-3.31), transient ischaemic attack and cerebrovascular accident (OR 1.97, 95% CI 0.94-4.10), multimorbidity (≥3 co-morbidities) (OR 1.80, 95% CI 1.07-3.03), depression (OR 1.79, 95% CI 1.00-3.23), and polypharmacy (OR 0.65, 95% CI 0.40-1.05). The prevalence of a high ACB score and falls were 1.8% and 16.8%, respectively. Approximately one in two older adults had polypharmacy. We observed a non-significant inverse relationship between polypharmacy and falls. This may possibly suggest appropriate polypharmacy and closer monitoring applied in geriatric settings, which requires further investigation.
- 1 January 2026
- Vol. 58 (1) , 67-76
Components of Sarcopenia and Frailty in Relation to Cognitive Impairment in Older Adults: An Ambispective Cohort Study from a Tertiary Hospital.
Sarcopenia and frailty are common geriatric syndromes that may contribute to mild cognitive impairment (MCI). Evidence regarding the independent roles of individual sarcopenia components and frailty in MCI remains limited in low- and middle-income countries. This study evaluated the association between sarcopenia components, frailty, and MCI among older adults in Indonesia. An ambispective cohort study was conducted among adults aged ≥60 years attending the Geriatric Outpatient Clinic of Dr. Cipto Mangunkusumo National General Hospital, Jakarta. Sarcopenia components were assessed using SARC-Calf (low muscle mass indicator), handgrip strength, and the five-times sit-to-stand test. Frailty was evaluated using the FRAIL scale. Cognitive function was assessed using the Rapid Cognitive Screening. Multivariate log-binomial or Poisson regression with robust variance was used to estimate adjusted risk ratios (RRs) for MCI. A total of 121 participants (median age 74 years; 68.6% female) were included, with an MCI prevalence of 21.5%. After adjustment for confounders, low muscle mass indicator (RR 2.206; 95% CI 1.045-4.652) and low muscle strength (RR 3.006; 95% CI 1.202-7.517) were independently associated with MCI. Low physical performance (RR 1.773; 95% CI 0.796-3.773) and frailty (RR 1.086; 95% CI 0.377-3.134) were not significantly associated with MCI. Low muscle mass indicators and reduced muscle strength were independently associated with MCI, supporting the integration of simple sarcopenia screening tools into routine geriatric cognitive assessment.
- 1 January 2026
- Vol. 58 (1) , 67-76
Components of Sarcopenia and Frailty in Relation to Cognitive Impairment in Older Adults: An Ambispective Cohort Study from a Tertiary Hospital.
Sarcopenia and frailty are common geriatric syndromes that may contribute to mild cognitive impairment (MCI). Evidence regarding the independent roles of individual sarcopenia components and frailty in MCI remains limited in low- and middle-income countries. This study evaluated the association between sarcopenia components, frailty, and MCI among older adults in Indonesia. An ambispective cohort study was conducted among adults aged ≥60 years attending the Geriatric Outpatient Clinic of Dr. Cipto Mangunkusumo National General Hospital, Jakarta. Sarcopenia components were assessed using SARC-Calf (low muscle mass indicator), handgrip strength, and the five-times sit-to-stand test. Frailty was evaluated using the FRAIL scale. Cognitive function was assessed using the Rapid Cognitive Screening. Multivariate log-binomial or Poisson regression with robust variance was used to estimate adjusted risk ratios (RRs) for MCI. A total of 121 participants (median age 74 years; 68.6% female) were included, with an MCI prevalence of 21.5%. After adjustment for confounders, low muscle mass indicator (RR 2.206; 95% CI 1.045-4.652) and low muscle strength (RR 3.006; 95% CI 1.202-7.517) were independently associated with MCI. Low physical performance (RR 1.773; 95% CI 0.796-3.773) and frailty (RR 1.086; 95% CI 0.377-3.134) were not significantly associated with MCI. Low muscle mass indicators and reduced muscle strength were independently associated with MCI, supporting the integration of simple sarcopenia screening tools into routine geriatric cognitive assessment.
- 1 January 2026
- Vol. 58 (1) , 52-58
Effects of Garcinia mangostana Peel Extract on Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review of Human Studies.
Type 2 diabetes mellitus (T2DM) is a major global health concern characterized by insulin resistance, hyperglycemia, and chronic inflammation. Interest in natural adjunctive therapies has increased, particularly in mangosteen (Garcinia mangostana), which contains xanthone compounds in the peel with potential antidiabetic properties. This systematic review followed PRISMA 2020 guidelines. Literature searches were conducted using PubMed, Google Scholar, and ClinicalKey up to December 2022 for studies assessing mangosteen peel extract (MPE) or α-mangostin in diabetic human subjects. Eligible studies included randomized controlled and quasi-experimental trials reporting glycemic or metabolic outcomes. Risk of bias was evaluated using the Cochrane RoB tool. The primary result of this study is to evaluate the effects of mangosteen peel extract supplementation on key glycemic outcomes in patients with T2DM, specifically fasting blood glucose (FBG), HOMA-IR, and HbA1c. A total of two studies (n=2) met the inclusion criteria. A randomized controlled pilot trial reported significant improvement in insulin sensitivity (HOMA-IR -53.2% vs -15.2%; p = 0.004) after 26 weeks of standardized mangosteen extract. A small quasi-experimental study reported a significant reduction in FBG following 7 days of mangosteen peel decoction. Limited clinical evidence indicates that mangosteen peel extract may improve insulin sensitivity and lower fasting glucose in T2DM. However, the conclusions are limited by the small number of available studies, the short follow-up duration in one trial, and variability in extract preparation. Mangosteen peel extract demonstrates promising glycemic benefits, including improved insulin sensitivity and reduced fasting glucose. However, the available evidence remains limited by small sample sizes, short follow-up periods, and heterogeneity in extract formulations. Larger randomized controlled trials using standardized preparations are required before clinical recommendations can be made.
- 1 January 2026
- Vol. 58 (1) , 52-58
Effects of Garcinia mangostana Peel Extract on Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review of Human Studies.
Type 2 diabetes mellitus (T2DM) is a major global health concern characterized by insulin resistance, hyperglycemia, and chronic inflammation. Interest in natural adjunctive therapies has increased, particularly in mangosteen (Garcinia mangostana), which contains xanthone compounds in the peel with potential antidiabetic properties. This systematic review followed PRISMA 2020 guidelines. Literature searches were conducted using PubMed, Google Scholar, and ClinicalKey up to December 2022 for studies assessing mangosteen peel extract (MPE) or α-mangostin in diabetic human subjects. Eligible studies included randomized controlled and quasi-experimental trials reporting glycemic or metabolic outcomes. Risk of bias was evaluated using the Cochrane RoB tool. The primary result of this study is to evaluate the effects of mangosteen peel extract supplementation on key glycemic outcomes in patients with T2DM, specifically fasting blood glucose (FBG), HOMA-IR, and HbA1c. A total of two studies (n=2) met the inclusion criteria. A randomized controlled pilot trial reported significant improvement in insulin sensitivity (HOMA-IR -53.2% vs -15.2%; p = 0.004) after 26 weeks of standardized mangosteen extract. A small quasi-experimental study reported a significant reduction in FBG following 7 days of mangosteen peel decoction. Limited clinical evidence indicates that mangosteen peel extract may improve insulin sensitivity and lower fasting glucose in T2DM. However, the conclusions are limited by the small number of available studies, the short follow-up duration in one trial, and variability in extract preparation. Mangosteen peel extract demonstrates promising glycemic benefits, including improved insulin sensitivity and reduced fasting glucose. However, the available evidence remains limited by small sample sizes, short follow-up periods, and heterogeneity in extract formulations. Larger randomized controlled trials using standardized preparations are required before clinical recommendations can be made.
- Open Access
- 22 October 2025
- Published by Universitas Mulawarman in Journal Of Tropical Pharmacy And Chemistry
- p. 123-139
The Impact of Flavonoids from Fruits and Vegetables on Cognitive Function in Dementia
Flavonoids are polyphenolic phytochemicals abundant in fruits and vegetables that have attracted attention for their potential neuroprotective effects. Dementia, marked by progressive cognitive decline, has limited effective treatments, prompting interest in nutritional approaches. This review synthesizes existing preclinical and clinical evidence of flavonoids-particularly anthocyanins, flavanols, flavonols, and isoflavones-and their potential effects on different cognitive domains and dementia subtypes. Mechanistic pathways (antioxidant, anti-inflammatory, neuroplasticity, vascular, gut-brain axis) are discussed, along with factors influencing flavonoid efficacy, methodological limitations, and directions for future research. Overall, the evidence suggests modest but promising cognitive benefits of dietary flavonoids, especially for Alzheimer's disease, though more rigorous human trials are needed. Recommendations for dietary guidance and translational implications are highlighted.
- 22 October 2025
- Published by Universitas Mulawarman in Journal Of Tropical Pharmacy And Chemistry
- p. 123-139
Open AccessThe Impact of Flavonoids from Fruits and Vegetables on Cognitive Function in Dementia
Flavonoids are polyphenolic phytochemicals abundant in fruits and vegetables that have attracted attention for their potential neuroprotective effects. Dementia, marked by progressive cognitive decline, has limited effective treatments, prompting interest in nutritional approaches. This review synthesizes existing preclinical and clinical evidence of flavonoids-particularly anthocyanins, flavanols, flavonols, and isoflavones-and their potential effects on different cognitive domains and dementia subtypes. Mechanistic pathways (antioxidant, anti-inflammatory, neuroplasticity, vascular, gut-brain axis) are discussed, along with factors influencing flavonoid efficacy, methodological limitations, and directions for future research. Overall, the evidence suggests modest but promising cognitive benefits of dietary flavonoids, especially for Alzheimer's disease, though more rigorous human trials are needed. Recommendations for dietary guidance and translational implications are highlighted.
- Open Access
- 4 August 2025
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 34 (4)
Formulation of mice diet with low cholecalciferol content
BACKGROUND Vitamin D deficiency has been linked to autoimmune diseases, cancer, and cardiovascular diseases. Although 1 study attempted to elucidate the ingredients required to make this diet, the process remained unclear. Hence, this study aimed to customize a low cholecalciferol diet with good tolerability in mice. METHODS We customized a diet containing a normal cholecalciferol content (1 IU/g diet) and another with a low cholecalciferol content (0.05 IU/g diet). Samples from both diets were sent to an independent laboratory to ensure that the levels of cholecalciferol, phosphorus, and calcium present in the custom diets matched our calculations. 5 mice were fed the customized normal cholecalciferol diet for 1 week to assess tolerability. Tolerability was assessed by measuring the amount of food consumed, weight gained, and the presence of any adverse events. RESULTS Cholecalciferol, phosphorous, and calcium levels in both diets satisfactorily matched our calculations. The diet was well tolerated without any adverse events or mortalities. The mice consumed an adequate amount of food (mean: 5.34 [0.08] g diet/day, 95% confidence interval [CI]: 5.12–5.56; 19.38 kcal, fat: 0.43 g, protein: 0.14 g, carbohydrates: 3.16 g, and cholecalciferol: 0.007 mg) and gained a slight amount of weight by the end of the experiment (mean: 1.86 [0.46] g, 95% CI: 0.58–3.14). CONCLUSIONS This study successfully created 2 custom diets with quantified cholecalciferol contents. This animal model may prove valuable for studies involving vitamin D.
- 4 August 2025
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 34 (4)
Open AccessFormulation of mice diet with low cholecalciferol content
BACKGROUND Vitamin D deficiency has been linked to autoimmune diseases, cancer, and cardiovascular diseases. Although 1 study attempted to elucidate the ingredients required to make this diet, the process remained unclear. Hence, this study aimed to customize a low cholecalciferol diet with good tolerability in mice. METHODS We customized a diet containing a normal cholecalciferol content (1 IU/g diet) and another with a low cholecalciferol content (0.05 IU/g diet). Samples from both diets were sent to an independent laboratory to ensure that the levels of cholecalciferol, phosphorus, and calcium present in the custom diets matched our calculations. 5 mice were fed the customized normal cholecalciferol diet for 1 week to assess tolerability. Tolerability was assessed by measuring the amount of food consumed, weight gained, and the presence of any adverse events. RESULTS Cholecalciferol, phosphorous, and calcium levels in both diets satisfactorily matched our calculations. The diet was well tolerated without any adverse events or mortalities. The mice consumed an adequate amount of food (mean: 5.34 [0.08] g diet/day, 95% confidence interval [CI]: 5.12–5.56; 19.38 kcal, fat: 0.43 g, protein: 0.14 g, carbohydrates: 3.16 g, and cholecalciferol: 0.007 mg) and gained a slight amount of weight by the end of the experiment (mean: 1.86 [0.46] g, 95% CI: 0.58–3.14). CONCLUSIONS This study successfully created 2 custom diets with quantified cholecalciferol contents. This animal model may prove valuable for studies involving vitamin D.
- Open Access
- 31 March 2025
- Published by The Korean Geriatrics Society in Annals of Geriatric Medicine and Research
- Vol. 29 (1) , 91-101
Co-occurrence of Frailty, Possible Sarcopenia, and Malnutrition in Community-Dwelling Older Outpatients: A Multicentre Observational Study
Background: The co-occurrence of frailty, sarcopenia, and malnutrition was well studied in inpatient and nursing home settings, which was associated with higher risk of all-cause mortality. Multicentre data in community-dwelling outpatient setting were lacking. We aimed to find the prevalence of frailty, possible sarcopenia and malnutrition, their overlap and the associated factors in community-dwelling older outpatients.Methods: We collected data from community-dwelling outpatients aged ≥60 years in Indonesian geriatric care centres to conduct this cross-sectional study with bivariate and multivariable analyses. Frailty, possible sarcopenia, and malnutrition diagnoses were based on FRAIL scale, Asian Working Group for Sarcopenia 2019 consensus, and Mini Nutritional Assessment Short Form, respectively.Results: The prevalence of frailty, possible sarcopenia, and malnutrition in community-dwelling older outpatients were 13.6%, 45.5%, and 5.3%, respectively. The prevalence of co-occurrence of frailty, possible sarcopenia and malnutrition was 3.3%. It was associated with transient ischemic attack (TIA) and cerebrovascular accident (odds ratio [OR]=5.53, 95% confidence interval [CI] 1.48–20.61), cognitive impairment (OR=3.70, 95% CI 1.21–11.31), and dependent functional capacity (OR=11.62, 95% CI 3.38–39.99). Overlap of three evaluated syndromes was found in 24.1%, 7.2%, and 61.3% of subjects with frailty, possible sarcopenia, and malnutrition, respectively. It was characterized by a substantial proportion of female sex, older adults with low educational attainment, diabetes mellitus, hypertension, cognitive impairment, multimorbidity, and dependent functional status.Conclusion: Approximately 1 in 30 community-dwelling older outpatients had overlapping frailty, possible sarcopenia, and malnutrition. The condition is associated with TIA and cerebrovascular accident, cognitive impairment, and dependent functional capacity. Standardized screening in community-dwelling older population is necessary.
- 31 March 2025
- Published by The Korean Geriatrics Society in Annals of Geriatric Medicine and Research
- Vol. 29 (1) , 91-101
Open AccessCo-occurrence of Frailty, Possible Sarcopenia, and Malnutrition in Community-Dwelling Older Outpatients: A Multicentre Observational Study
Background: The co-occurrence of frailty, sarcopenia, and malnutrition was well studied in inpatient and nursing home settings, which was associated with higher risk of all-cause mortality. Multicentre data in community-dwelling outpatient setting were lacking. We aimed to find the prevalence of frailty, possible sarcopenia and malnutrition, their overlap and the associated factors in community-dwelling older outpatients.Methods: We collected data from community-dwelling outpatients aged ≥60 years in Indonesian geriatric care centres to conduct this cross-sectional study with bivariate and multivariable analyses. Frailty, possible sarcopenia, and malnutrition diagnoses were based on FRAIL scale, Asian Working Group for Sarcopenia 2019 consensus, and Mini Nutritional Assessment Short Form, respectively.Results: The prevalence of frailty, possible sarcopenia, and malnutrition in community-dwelling older outpatients were 13.6%, 45.5%, and 5.3%, respectively. The prevalence of co-occurrence of frailty, possible sarcopenia and malnutrition was 3.3%. It was associated with transient ischemic attack (TIA) and cerebrovascular accident (odds ratio [OR]=5.53, 95% confidence interval [CI] 1.48–20.61), cognitive impairment (OR=3.70, 95% CI 1.21–11.31), and dependent functional capacity (OR=11.62, 95% CI 3.38–39.99). Overlap of three evaluated syndromes was found in 24.1%, 7.2%, and 61.3% of subjects with frailty, possible sarcopenia, and malnutrition, respectively. It was characterized by a substantial proportion of female sex, older adults with low educational attainment, diabetes mellitus, hypertension, cognitive impairment, multimorbidity, and dependent functional status.Conclusion: Approximately 1 in 30 community-dwelling older outpatients had overlapping frailty, possible sarcopenia, and malnutrition. The condition is associated with TIA and cerebrovascular accident, cognitive impairment, and dependent functional capacity. Standardized screening in community-dwelling older population is necessary.